RxDoctor Payments Data

Gabrielle Anderson, DO

Family Medicine · Casselberry, FLNPI 1841828498

Payments from drug & device makers

$810in general payments, 2019–2025

Across 8 payments — averaging $101.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$125
  • Amgen$124
  • Otsuka America Pharmaceutical, Inc.$122
  • Exact Sciences$116
  • Eisai Inc.$106
  • Teva Pharmaceuticals USA, Inc.$98
  • plus $119 from 2 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$278,781
Medicare patients
492
Services billed
2,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$81,679
BiktarvyBictegrav/Emtricit/Tenofov Ala21$80,053
NuplazidPimavanserin Tartrate18$43,256
XifaxanRifaximin30$42,881
ProcritEpoetin Alfa32$26,946
Xtampza ErOxycodone Myristate37$14,048
TrulicityDulaglutide22$13,818
JardianceEmpagliflozin41$12,821
BrilintaTicagrelor59$12,316
NuedextaDextromethorphan Hbr/Quinidine15$10,671
Sevelamer Carbonate26$6,395
JentaduetoLinagliptin/Metformin Hcl13$5,899
Gabapentin155$4,035
XareltoRivaroxaban16$3,618
Atorvastatin Calcium206$3,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$98$18,72054 claims
Sanofi-aventis U.S. LLCLantus$21$1,51221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Casselberry

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →